Health Care • Biotechnology: Pharmaceutical Preparations
$0.30 ▲ +0.00
(+1.62%)
MKT CAP: $48.2M • VOL: 1.13M
52W L $0 52W H $2
ROARABLE / RQD
D- • 42/100
PIOTROSKI
2 / 9
MREO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $500.0K | $0 | $10.0M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$40.1M | -$47.4M | -$28.4M |
| Operating Margin % | -80.0% | — | -80.0% |
| Net Income (GAAP) | $41.9M | $43.3M | $29.5M |
| EBITDA (Normalized) | -$40.1M | -$47.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$31.0M | -$32.8M | -$21.1M |
| Capital Expenditures (CapEx) | $20.0K | $0 | — |
| Free Cash Flow (FCF) | -$31.0M | -$32.8M | -$21.1M |
| FCF Margin % | -80.0% | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $41.0M | $69.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $40.9M | $61.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MREO.